Fractyl Health Q1 net income $9.2M on non-cash warrant change; Revita pivotal data on track for early Q4

FRACTYL HEALTH, INC.

2026-Q1 EPS reported $0.06 vs consensus -$0.16 ▲ beat (+136.8%)

Q1 R&D expenses $15.6M (down from $19.4M YoY); SG&A $5.2M; adjusted EBITDA -$18.0M.
Cash $63.2M; runway into early 2027, beyond anticipated pivotal data readout.
Revita REMAIN-1 Pivotal topline 6-month data expected early Q4 2026; FDA De Novo submission target late Q4 2026.
1-year REVEAL-1 Cohort data in Q2 2026; 1-year randomized REMAIN-1 Midpoint data in Q3 2026.
RJVA-001 first-in-human dosing and preliminary data expected in H2 2026 after Netherlands CTA authorization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FRACTYL HEALTH, INC. reported the quarter ended March 31, 2026 results: net income $9.2 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2026
Net income: $9.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Fractyl Health, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

FRACTYL HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-219365

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.